Turner, N. A., Cosgrove, S. E., Doernberg, S. B., Jenkins, T. C., Boucher, H. W., Jones, M., … Holland, T. L. (2026). Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial (Accepted). CMI Communications, 3(2), 105183–105183. https://doi.org/10.1016/j.cmicom.2026.105183

Turner, Nicholas A., Sara E. Cosgrove, Sarah B. Doernberg, Timothy C. Jenkins, Helen W. Boucher, Mark Jones, Daniel Ionescu, et al. “Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial (Accepted).” CMI Communications 3, no. 2 (July 2026): 105183–105183. https://doi.org/10.1016/j.cmicom.2026.105183.

Turner NA, Cosgrove SE, Doernberg SB, Jenkins TC, Boucher HW, Jones M, et al. Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial (Accepted). CMI Communications. 2026 Jul;3(2):105183–105183.

Turner, Nicholas A., et al. “Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial (Accepted).” CMI Communications, vol. 3, no. 2, Elsevier BV, July 2026, pp. 105183–105183. Crossref, doi:10.1016/j.cmicom.2026.105183.

Turner NA, Cosgrove SE, Doernberg SB, Jenkins TC, Boucher HW, Jones M, Ionescu D, Saulay M, Engelhardt M, Fowler VG, Holland TL. Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial (Accepted). CMI Communications. Elsevier BV; 2026 Jul;3(2):105183–105183.